-+ 0.00%
-+ 0.00%
-+ 0.00%

US FDA Wraps Up Inspection of Xspray Pharma's Contract Manufacturer's Facility in Italy

MT Newswires·11/20/2026 12:09:33
Listen to the news
12:09 PM EST, 11/20/2026 (MT Newswires) -- The US Food and Drug Administration completed a follow-up inspection of Xspray Pharma's (XSPRAY.ST) contract manufacturer NerPharMa's facility in Italy. The review resulted in a Form FDA 483 listing observations that NerPharMa must address by Dec. 9, according to a Friday release. The Swedish pharmaceutical company said none of the observations concern its manufacturing lines or its Dasynoc and Nilopki drugs. NerPharMa has started addressing the findings, with the regulator expected to classify the inspection within 90 days.